Can Lowering Cholesterol Prevent Or Treat Alzheimer’s?

TL;DR

For listenersOffer from Amazon

Turn your wind-down time into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

A subgroup analysis from a Phase 3 trial found lower blood levels of the Alzheimer’s biomarker pTau-217 among ApoE4 carriers taking obicetrapib, a cholesterol-lowering drug. The result does not show that the drug prevents or treats Alzheimer’s; a Phase 2b study is now testing biomarker effects in people with Alzheimer’s hallmarks but no symptoms. Observational statin findings are suggestive, while earlier randomized trials did not show cognitive benefit.

A Phase 3 study of obicetrapib, a cholesterol-lowering drug being developed by NewAmsterdam Pharma, found lower blood levels of the Alzheimer’s biomarker pTau-217 in a subgroup of participants who carried the ApoE4 risk gene. The finding is not evidence that lowering cholesterol prevents or treats Alzheimer’s, but the company has begun a separate Phase 2b trial to test whether the drug changes Alzheimer’s biomarkers in people with disease hallmarks but no symptoms.

The Phase 3 study tested obicetrapib in people with heart disease or a genetic form of high cholesterol. In an analysis of 1,727 participants with ApoE4, the drug was associated with lower blood pTau-217, a biomarker used to help diagnose Alzheimer’s in people with cognitive impairment. The source report does not state the size of the biomarker change or show that participants experienced improved memory, thinking or daily function.

NewAmsterdam Pharma has enrolled the first participant in a Phase 2b Alzheimer’s trial. The study is testing whether a year of treatment can lower Alzheimer’s biomarkers in people who have signs associated with the disease but no symptoms. Biomarker changes are an early research signal; they do not by themselves establish clinical benefit.

Evidence on statins, another class of cholesterol-lowering drugs, is mixed. A Danish analysis of electronic health records from more than 130,000 people with Type 2 diabetes found that starting statins earlier was associated with a 15% lower dementia risk over a decade; starting later was associated with a 10% reduction. Because this was an observational study, it cannot establish that statins caused the difference. Earlier randomized trials did not show that statins treated cognitive decline, and a trial in healthy adults over 70 did not find a dementia-prevention effect.

From Cholesterol Levels to Brain Biomarkers

The findings reopen a research question without resolving it: whether changing cholesterol pathways can affect Alzheimer’s biology, and whether any such effect can alter a person’s cognition or disease course. For patients and families, the distinction matters. A change in a blood test is not proof of prevention, treatment or slower decline, and the current evidence does not support taking a cholesterol drug specifically for Alzheimer’s outside a clinical trial.

The work also points to differences between drug classes. Statins lower cholesterol in the blood but do not readily reach the brain, according to the report. Obicetrapib is a CETP inhibitor that limits cholesterol being transferred into LDL. The biomarker result has led researchers to consider whether this drug may affect processes relevant to the brain, but the mechanism and clinical importance remain unproven.

Why Statin Findings Have Diverged

Cholesterol is transported through the body by particles including LDL and HDL. ApoE4, a genetic risk factor for Alzheimer’s and cardiovascular disease, also affects cholesterol processing. The report notes that cholesterol in the blood cannot cross into the brain; researchers are studying whether abnormalities in the brain’s own cholesterol metabolism contribute to Alzheimer’s.

Statins are widely used to reduce cardiovascular risk, including stroke risk in people with Type 2 diabetes. But randomized trials conducted more than a decade ago did not show that statins treated cognitive decline. Observational studies can identify associations over longer periods, yet people who take medication may differ from those who do not in healthcare access, medical knowledge or health behaviors. Those differences make cause and effect difficult to determine.

““It’s unknown.””

— Dr. David Knopman, neurologist at the Mayo Clinic, as quoted by Being Patient

Biomarker Change Is Not Clinical Benefit

The available report does not give the magnitude of the pTau-217 change, establish that obicetrapib reaches the brain, or show an effect on cognition, dementia onset or daily functioning. It also does not say whether the biomarker finding will be replicated in the Alzheimer’s-focused trial. A reduction in a blood marker may be scientifically useful, but its meaning for patients is not yet known.

The statin evidence has limits as well. The Danish study was observational, so differences between people who started treatment and those who did not could help explain the association. Randomized trials have not established a dementia-prevention benefit. Researchers also face practical barriers to long-term studies, including cost and limited commercial incentives for testing off-patent drugs.

The Alzheimer’s Trial Will Test Biomarkers

The next reported milestone is the Phase 2b trial of obicetrapib, which will assess whether a year of treatment lowers Alzheimer’s biomarkers in participants who have disease hallmarks but no symptoms. The source report does not provide the planned enrollment, expected completion date or a timetable for results.

To determine whether a biomarker effect translates into meaningful benefit, later research would need to examine clinical outcomes such as cognition and function, as well as safety and durability. Until those results are available, cholesterol-lowering drugs should be used for their established medical indications, not presented as proven Alzheimer’s prevention or treatment. People should discuss medication decisions with a qualified health professional.

Key Questions

Does obicetrapib prevent or treat Alzheimer’s?

That has not been shown. A Phase 3 study reported lower pTau-217 blood levels in a subgroup of ApoE4 carriers, but it did not establish an effect on Alzheimer’s symptoms, disease progression or dementia risk.

What did the statin study find?

An observational analysis of more than 130,000 people with Type 2 diabetes associated starting statins earlier with a 15% lower dementia risk over a decade; later initiation was associated with a 10% reduction. The study cannot prove statins caused those differences.

Why might a blood biomarker result matter?

pTau-217 is a blood biomarker used to help diagnose Alzheimer’s in people with cognitive impairment. A change may guide further research, but biomarker movement is not the same as improved health or prevention of disease.

Should people take cholesterol drugs to prevent Alzheimer’s?

The reported evidence does not establish that cholesterol-lowering drugs prevent or treat Alzheimer’s. Such medicines should be taken for a clinician-recommended indication, and people should consult a qualified health professional about their own care.

Source: rss